Aliud Pharma GmbH
Aliud Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe. Founded in 2004, the company has established itself as a trusted provider of high-quality generic medicines, focusing on therapeutic areas such as oncology, cardiology, and infectious diseases. With a commitment to innovation and quality, Aliud Pharma offers a diverse portfolio of products that are distinguished by their efficacy and safety. The company’s dedication to rigorous research and development has led to significant milestones, including the successful launch of numerous generic formulations that meet stringent regulatory standards. Recognised for its market position, Aliud Pharma continues to expand its reach, contributing to improved healthcare outcomes while maintaining a strong emphasis on sustainability and patient-centric solutions.
DitchCarbon Score
How does Aliud Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aliud Pharma GmbH's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aliud Pharma GmbH, headquartered in Germany, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of STADA Arzneimittel Aktiengesellschaft, which may influence its climate commitments and emissions reporting. As part of its corporate family, Aliud Pharma GmbH inherits climate initiatives and targets from STADA Arzneimittel Aktiengesellschaft. However, there are no documented reduction targets or specific climate pledges listed for Aliud Pharma GmbH itself. The absence of emissions data and reduction initiatives suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. In the broader context, companies in the pharmaceutical sector are increasingly focusing on sustainability and carbon reduction, often aligning with industry standards and frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). It is essential for Aliud Pharma GmbH to develop and communicate its climate commitments to align with these industry trends and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 31,639,700 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,032,800 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aliud Pharma GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
